Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Needling with intralesional tetracosactide plus NB-UVB for refractory vitiligo
IRCT20190515043600N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tetracosactide hexaacetate in Vitiligo (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Grade of repigmentation and New treatment approach with least side effects and high effectiveness. Started Mar 2018; status: completed.
02
Drugs
tetracosactide hexaacetate
03
Conditions
Vitiligo
Beyond the preview
Go deeper on IRCT20190515043600N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190515043600N1.